Search results
Results from the WOW.Com Content Network
Amgen Inc. v. Sanofi, 598 U.S. 594 (2023), is a United States Supreme Court case in which the Court held that Amgen's two patent applications on cholesterol-lowering drugs failed to satisfy the enablement clause of §112 of the Patent Act, 35 U.S.C. § 112(a).
In November, Amgen awarded a $2 million grant to the CDC Foundation to launch the latter's EmPOWERED Health Program, promoting patient engagement in decision making for their cancer treatment. [85] In December, the FDA approved Avsola (infliximab-axxq). [86] 2020: In April, Amgen established Amgen K.K. as the company's wholly-owned affiliate in ...
Kirin-Amgen, Inc. v Hoechst Marion Roussel Ltd. [1] is a decision by the House of Lords of England and Wales. The judgment was issued on 21 October 2004 and relates to the scope to be accorded to patent claims, including the doctrine of equivalents .
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small cell lung ...
In this example a company should prefer product B's risk and payoffs under realistic risk preference coefficients. Multiple-criteria decision-making (MCDM) or multiple-criteria decision analysis (MCDA) is a sub-discipline of operations research that explicitly evaluates multiple conflicting criteria in decision making (both in daily life and in settings such as business, government and medicine).
The target population for these chronic diseases necessitates more advanced drug administration options to mitigate the adverse effects of conventional drug delivery methods. Drug delivery devices are intended to reduce side effects by optimizing drug presence at the target site, thereby reducing dosage and associated side effects.
(Reuters) -Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug ...
An illustrative landmark decision on the issue of "written description" was University of Rochester v. Searle, [12] related to patents on COX-2 inhibitors. In the early 1990s scientists at the University of Rochester discovered two disctinct cyclooxygenases, referred to as COX-1 and COX-2. For most patents it is desirable to inhibit COX-2 and ...